

ACQUITY UPLC I-Class/Xevo TQD IVD System: Analytical Performance for Antibiotics

Stephen Balloch, Lisa J. Calton, Gareth Hammond

Waters Corporation

This is an Application Brief and does not contain a detailed Experimental section.

For research use only. Not for use in diagnostic procedures.

Introduction

The Waters ACQUITY UPLC I-Class/Xevo TQD IVD System enables the quantification of organic compounds in human biological liquid matrices.

This document describes a test of the analytical performance of the ACQUITY UPLC I-Class/Xevo TQD IVD System for the analysis of ampicillin, azithromycin, cefazolin, cefepime, cefotaxime, ceftazidime, chloramphenicol, ciprofloxacin, clindamycin, daptomycin, flucloxacillin, linezolid, meropenem, piperacillin, sulbactam, and tazobactam in plasma.

Experimental

The ACQUITY UPLC I-Class/Xevo TQD IVD System was controlled by MassLynx Software (v4.2) and the data

processed using the TargetLynx XS Application Manager. Calibrators and Quality Controls were prepared by spiking commercially available reference material in plasma and the samples were processed using the following conditions:

Sample Preparation Conditions

A 50 µL sample was processed with methanol and centrifuged, then subsequently diluted with acidified water prior to analysis.

LC Conditions

Column:	ACQUITY UPLC BEH C_{18, 1.7 μm , 2.1 mm x 100 mm
Mobile phase A:	0.1% ammonia in water
Mobile phase B:	Methanol
Flow rate:	0.5 mL/min
Gradient:	90% A initial, gradient 6 until 0% A at 3.00
	minutes, hold until 4.00 minutes, 90% A gradient 6
	at 4.10 minutes, then hold until 5.00 minutes

Gradient

Time (minutes)	Flow (mL/min)	% Mobile phase A	% Mobile phase B	Curve
Initial	0.5	90	10	Initial
3.00	0.5	0	100	6
4.00	0.5	0	100	6
4.01	0.5	90	10	6
5.00	0.5	90	10	6

MS Conditions

Resolution:	MS1 (0.75 FWHM), MS2 (0.75FWHM)		
Acquisition mode:	MRM		
Polarity:	ESI (+/-)		

Results and Discussion

Chromatographic selectivity of a range of antibiotics using the ACQUITY UPLC I-Class/ Xevo TQD IVD System is illustrated in Figure 1. Performance characteristics of the antibiotics are shown in Table 1.

100	coftazidime (ESI+) m2 547.1>485.1
100	a "aba" aba" aba" aba" "ka" "ka" "ka" "k
100	e ebb [°] aka [°] eb [°] ebb [°] e
04 0.4	o "sio" sio" sio" sio" sio" sio" sio" si
100	a "sốo" eka" she "ske" the "the "the "the "the "the "the "th
100	w "ski" ski "ski" i tik "tik "tik" tik" tik" tik" tik"
100	o "olo" olo" olo" (150 '150 '150 '150 '150 '150 '150 '150 '
100	n obn obn obn obn obn obn obn obn obn ob
100	n "non" eka "oka" eka "oka" ita "ta" ita" ita" ita" ita" ita" ita
10	a "οδο" eδο" οδο "οδο" το
100	ar "olo" ello" ello "olo" rilo" rilo
100	a "elo" elo" elo" elo "elo" to" to" to" to" to" to" to" to" to" t
100	a "sio" ello "sio" sio" sio" sio" sio" sio" sio" si
04 0.4	no "sto "ello" ello" ello" ello" "tio" tio" tio" tio" tio" tio" tio" t
0-0-0-0-0-0-0-0-0-0-0-0-0-0-0-0-0-0-0-	n" stor e kan" s tor e kan" s tor "s tor" s tor "s tor" s
100	o "sio" ello "sio" sio" sio" sio" sio" sio" sio" si

Figure 1. Chromatographic selectivity of a range of

antibiotics using the ACQUITY UPLC I-Class/ Xevo TQD IVD System.

Compound	Calibration range* (µg/mL)	LLOQ (µg/mL)	Linear range µg/mL	Total precision	Repeatability
Ampicillin	0.5-50	0.375	0.5-50	≤7.8%	≤7.6%
Azithromycin	0.005-0.5	0.00375	0.00374-0.650	≤8.3%	≤2.6%
Cefazolin	1–100	1	0.748-130	≤12.2%	≤11.6%
Cefepime	1–100	0.9	0.748-130	≤11.5%	≤11.1%
Cefotaxime	0.5-50	0.375	0.374-65	≤9.2%	≤4.1%
Ceftazidime	1–100	0.75	0.975-101	≤8.2%	≤4.7%
Chloramphenicol	0.5-50	0.375	0.374-65	≤10.9%	≤4.2%
Ciprofloxacin	0.1–10	0.075	0.0748-13	≤12.5%	≤6.1%
Clindamycin	0.1–10	0.075	0.0975-10.1	≤5.8%	≤2.8%
Daptomycin	2-200	1.5	1.76-231	≤7.6%	≤4.3%
Flucloxacillin	1–100	1	0.748-130	≤9.6%	≤5.5%
Linezolid	0.5-50	0.375	0.374-65	≤6.5%	≤4.1%
Meropenem	1–100	0.9	0.975-130	≤12.4%	≤10.6%
Piperacillin	2-200	0.5	1.5-260	≤9.3%	≤3.6%
Sulbactam	1–100	0.75	0.748-130	≤8.6%	≤8.6%
Tazobactam	0.5-50	0.375	0.488-50.7	≤11.2%	≤8.1%

Table 1. Performance characteristics of the analytes evaluated.

*Calibration Range was defined by linear fit where $r^2 > 0.995$ for cefepime, daptomycin, piperacillin and sulbactam; for all other analytes a quadratic fit was used. LLOQ defined by S/N (PtP) >10 with %RSD $\leq 20\%$ and $\leq 15\%$. %RSD at LLOQ determined through analytical sensitivity experiments performed over five occasions (n=50). Total precision and repeatability of QCs performed over 5 occasions in plasma (n=25). Data was collected in two runs.

Conclusion

The Waters ACQUITY UPLC I-Class/Xevo TQD IVD System has demonstrated the capability to analyze a panel of antibiotics in plasma.

Disclaimer

The analytical performance data presented here is for illustrative purposes only. Waters does not recommend or suggest analysis of the analytes described herein. These data are intended solely to demonstrate the performance capabilities of the system for analytes representative of those commonly analyzed using liquid chromatography and tandem mass spectrometry. Performance in an individual laboratory may differ due to a number of factors, including laboratory methods, materials used, intra-operator technique, and system

conditions. This document does not constitute a warranty of merchantability or fitness for any particular purpose, express or implied, including for the testing of the analytes in this analysis.

Featured Products

- ACQUITY UPLC I-Class/Xevo TQD IVD System https://www.waters.com/waters/nav.htm?cid=134831492
- MassLynx MS Software <https://www.waters.com/513662>
- <u>TargetLynx <https://www.waters.com/513791></u>

720007394, October 2021

 \wedge

© 2021 Waters Corporation. All Rights Reserved.